Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

CALASPARGASE PEGOL-MKNL for B precursor type acute leukaemia: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 12 adverse event reports in the FDA FAERS database where CALASPARGASE PEGOL-MKNL was used for B precursor type acute leukaemia.

Most Reported Side Effects for CALASPARGASE PEGOL-MKNL

Side Effect Reports % Deaths Hosp.
Hypersensitivity 155 30.7% 0 28
Anaphylactic reaction 76 15.1% 0 40
Pancreatitis 56 11.1% 3 26
Infusion related reaction 51 10.1% 0 24
Vomiting 37 7.3% 2 21
Tachycardia 20 4.0% 2 13
Nausea 19 3.8% 0 9
Cough 18 3.6% 0 13
Hypertriglyceridaemia 18 3.6% 1 10
Neutropenia 15 3.0% 2 5
Venoocclusive liver disease 15 3.0% 5 13
Septic shock 14 2.8% 6 11
Pancreatitis acute 13 2.6% 0 9
Abdominal pain 12 2.4% 0 9
Hyperglycaemia 12 2.4% 1 5

Other Indications for CALASPARGASE PEGOL-MKNL

Acute lymphocytic leukaemia (156) Product used for unknown indication (122) B-cell type acute leukaemia (84) T-cell type acute leukaemia (29) Leukaemia (11) T-cell lymphoma (7) Precursor t-lymphoblastic lymphoma/leukaemia (6) Ductal adenocarcinoma of pancreas (5) Non-hodgkin's lymphoma (5)

Other Drugs Used for B precursor type acute leukaemia

BLINATUMOMAB (1,791) METHOTREXATE (1,067) VINCRISTINE (977) DEXAMETHASONE (662) CYTARABINE (644) CYCLOPHOSPHAMIDE (598) PEGASPARGASE (531) MERCAPTOPURINE (484) DOXORUBICIN (331) DAUNORUBICIN (274)

Related Pages

CALASPARGASE PEGOL-MKNL Full Profile All B precursor type acute leukaemia Drugs CALASPARGASE PEGOL-MKNL Demographics CALASPARGASE PEGOL-MKNL Timeline